EPO to grant patent notice to BioMimetic Therapeutics

Feb 2 2010

BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) announced today the European Patent Office (EPO) intends to grant patent application No. 05803356 titled “Platelet-Derived Growth Factor Compositions and Methods of Use Thereof”.

The allowed claims cover compositions of platelet derived growth factor (PDGF) combined with matrix materials having defined characteristics, which cover the Company’s novel recombinant protein-device combination product candidates, including Augment™ Bone Graft and Augment™ Injectable Bone Graft, as well as GEMESIS^™, which the Company previously sold to Luitpold Pharmaceuticals, Inc.

The new patent, which expires in 2025, will provide protection against the marketing of similar or generic versions of Augment, Augment Injectable, and GEMESIS in Europe. This notice from the EPO enhances the Company’s existing, strong patent portfolio, which includes a similar patent in the United States effective through 2025.

“This patent notice is an important development for BioMimetic, particularly relating to our future opportunities in Europe”

“This patent notice is an important development for BioMimetic, particularly relating to our future opportunities in Europe,” said Dr. Samuel Lynch, president and CEO of BioMimetic Therapeutics and the inventor on the patent. “Granting this patent will provide us with meaningful, long term protection for our platform technology in Europe, complementing the patent that was issued in the U.S. in 2009. The barriers to competitive entry that have now been established in the two biggest health care markets in the world are an important part of our global commercialization plans. Finally, we believe this patent further strengthens our position as an innovator in the field of orthobiologics utilizing recombinant human growth factors.”